Clinical Trial Update: A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers [Phase 2]

View source ↗

Summary

A Phase 2 multicenter open-label study to assess the immunogenicity of an investigational Hib vaccine (NU300) in toddlers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• NU300 Hib vaccine (Haemophilus influenzae type b vaccine NU300)

Snippet

Sponsor: Nuron Biotech Inc. | Conditions: Infectious Disease | Phase 2 | Status: UNKNOWN